Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: Preliminary findings

Hiroe Kakehashi, T. Ando, T. Minamizato, Y. Nakatani, T. Kawasaki, H. Ikeda, S. Kuroshima, A. Kawakami, I. Asahina

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.

Original languageEnglish
Pages (from-to)1558-1564
Number of pages7
JournalInternational Journal of Oral and Maxillofacial Surgery
Volume44
Issue number12
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Teriparatide
Osteonecrosis
Jaw
Osteogenesis
Peptide Hormones
Osteoporosis
Therapeutics
Amino Acids
Injections

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology

Cite this

Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw : Preliminary findings. / Kakehashi, Hiroe; Ando, T.; Minamizato, T.; Nakatani, Y.; Kawasaki, T.; Ikeda, H.; Kuroshima, S.; Kawakami, A.; Asahina, I.

In: International Journal of Oral and Maxillofacial Surgery, Vol. 44, No. 12, 01.01.2015, p. 1558-1564.

Research output: Contribution to journalArticle

Kakehashi, Hiroe ; Ando, T. ; Minamizato, T. ; Nakatani, Y. ; Kawasaki, T. ; Ikeda, H. ; Kuroshima, S. ; Kawakami, A. ; Asahina, I. / Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw : Preliminary findings. In: International Journal of Oral and Maxillofacial Surgery. 2015 ; Vol. 44, No. 12. pp. 1558-1564.
@article{88afb5876ab94e7eb1478c4ff118a967,
title = "Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: Preliminary findings",
abstract = "Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.",
author = "Hiroe Kakehashi and T. Ando and T. Minamizato and Y. Nakatani and T. Kawasaki and H. Ikeda and S. Kuroshima and A. Kawakami and I. Asahina",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ijom.2015.07.018",
language = "English",
volume = "44",
pages = "1558--1564",
journal = "International Journal of Oral and Maxillofacial Surgery",
issn = "0901-5027",
publisher = "Churchill Livingstone",
number = "12",

}

TY - JOUR

T1 - Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw

T2 - Preliminary findings

AU - Kakehashi, Hiroe

AU - Ando, T.

AU - Minamizato, T.

AU - Nakatani, Y.

AU - Kawasaki, T.

AU - Ikeda, H.

AU - Kuroshima, S.

AU - Kawakami, A.

AU - Asahina, I.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.

AB - Teriparatide is a synthetic polypeptide hormone that contains the 1-34 amino acid fragment of the recombinant human parathyroid hormone that stimulates bone formation. Currently, it is approved only for the treatment of osteoporosis. The outcomes of daily teriparatide injections for the treatment of bisphosphonate-related osteonecrosis of the jaw in 10 patients are reported here. Two of the 10 cases dropped out due to adverse events. Of the remaining eight cases, seven exhibited clinical improvement of the jaw-related symptoms of osteonecrosis and progression of the sequestration, while one case did not show improvement of the symptoms. Administration of teriparatide in patients with osteonecrosis of the jaw promotes bone formation and subsequent sequestration over a short period of time. These results suggest that adjunctive teriparatide therapy is a viable and effective option for treating osteonecrosis of the jaw.

UR - http://www.scopus.com/inward/record.url?scp=84960910687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960910687&partnerID=8YFLogxK

U2 - 10.1016/j.ijom.2015.07.018

DO - 10.1016/j.ijom.2015.07.018

M3 - Article

C2 - 26304604

AN - SCOPUS:84960910687

VL - 44

SP - 1558

EP - 1564

JO - International Journal of Oral and Maxillofacial Surgery

JF - International Journal of Oral and Maxillofacial Surgery

SN - 0901-5027

IS - 12

ER -